Scancell who have been developing a Covid-19 vaccine to cover multiple variants has announced success in the latest trial.

The latest release of information shows the positive data for COVIDITY and how this demonstrates the validation of the vaccine platform, including AvidiMab®. Scancell will continue to progress the program as it makes strides toward developing novel immunotherapies for the treatment of cancer and infectious disease.